Skip to main content
Journal cover image

Effectiveness and cost-effectiveness of an app and rewards-based intervention in type 2 diabetes: A randomised controlled trial.

Publication ,  Journal Article
Finkelstein, EA; Gardner, DS-L; Tham, KW; Gandhi, M; Cheung, YB; Bairavi, J; Lee, CF; Tan, NC; Yeoh, E; Lee, PC; Ho, ETL; Adamjee, T; Bee, YM ...
Published in: Diabetes Obes Metab
February 2025

AIM: Digital health interventions and economic incentives have shown promise in facilitating diabetes self-management, though evidence is limited. Therefore, this study aimed to evaluate the effectiveness and cost-effectiveness of a comprehensive app-based diabetes self-management programme with rewards for healthy behaviours and health outcomes. MATERIALS AND METHODS: The TRIal to slow the Progression Of Diabetes (TRIPOD) study was an open-label, parallel-group, randomised controlled trial conducted at Duke-NUS Medical School, Singapore. Adults with Type 2 Diabetes (diabetes), HbA1c of 7.5%-11.0% (inclusive) and taking at least one oral diabetes medication were eligible. In total, 269 participants were randomised across three arms [Usual care (UC): 117, diabetes management programme (DMP) (intervention without rewards): 36, DMP+ (intervention with rewards): 116]. Data were analysed using intention-to-treat analysis with change in HbA1c at month 12 between DMP+ and UC as the primary outcome. Cost-effectiveness of DMP+ relative to UC was also calculated. RESULTS: Mean HbA1c improved by 0.1% in UC and by 0.5% in DMP+ at 12 months, revealing a mean difference of 0.4% (95% confidence interval (CI): -0.70, -0.08, p = 0.015). The odds ratio of HbA1c improvements of >0.5% was 2.12 (95% CI: 1.17, 3.85, p = 0.013) for DMP+ relative to UC. The incremental cost-effectiveness ratio of DMP+ relative to UC was SGD8,516 (USD6,531) per quality-adjusted life year gained if effectiveness could be maintained with a single year of intervention. CONCLUSIONS: A comprehensive app-based diabetes self-management programme with rewards for healthy behaviours and health outcomes (DMP+) cost-effectively improved glycaemic control in Type 2 diabetes patients. Organizations focusing on value-based healthcare should consider subsidising similar interventions.

Duke Scholars

Published In

Diabetes Obes Metab

DOI

EISSN

1463-1326

Publication Date

February 2025

Volume

27

Issue

2

Start / End Page

729 / 739

Location

England

Related Subject Headings

  • Treatment Outcome
  • Singapore
  • Self-Management
  • Reward
  • Quality-Adjusted Life Years
  • Mobile Applications
  • Middle Aged
  • Male
  • Humans
  • Health Behavior
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Finkelstein, E. A., Gardner, D.-L., Tham, K. W., Gandhi, M., Cheung, Y. B., Bairavi, J., … Goh, S.-Y. (2025). Effectiveness and cost-effectiveness of an app and rewards-based intervention in type 2 diabetes: A randomised controlled trial. Diabetes Obes Metab, 27(2), 729–739. https://doi.org/10.1111/dom.16067
Finkelstein, Eric Andrew, Daphne Su-Lyn Gardner, Kwang Wei Tham, Mihir Gandhi, Yin Bun Cheung, Joann Bairavi, Chun Fan Lee, et al. “Effectiveness and cost-effectiveness of an app and rewards-based intervention in type 2 diabetes: A randomised controlled trial.Diabetes Obes Metab 27, no. 2 (February 2025): 729–39. https://doi.org/10.1111/dom.16067.
Finkelstein EA, Gardner DS-L, Tham KW, Gandhi M, Cheung YB, Bairavi J, et al. Effectiveness and cost-effectiveness of an app and rewards-based intervention in type 2 diabetes: A randomised controlled trial. Diabetes Obes Metab. 2025 Feb;27(2):729–39.
Finkelstein, Eric Andrew, et al. “Effectiveness and cost-effectiveness of an app and rewards-based intervention in type 2 diabetes: A randomised controlled trial.Diabetes Obes Metab, vol. 27, no. 2, Feb. 2025, pp. 729–39. Pubmed, doi:10.1111/dom.16067.
Finkelstein EA, Gardner DS-L, Tham KW, Gandhi M, Cheung YB, Bairavi J, Lee CF, Tan NC, Yeoh E, Lee PC, Ho ETL, Adamjee T, Bee YM, Goh S-Y. Effectiveness and cost-effectiveness of an app and rewards-based intervention in type 2 diabetes: A randomised controlled trial. Diabetes Obes Metab. 2025 Feb;27(2):729–739.
Journal cover image

Published In

Diabetes Obes Metab

DOI

EISSN

1463-1326

Publication Date

February 2025

Volume

27

Issue

2

Start / End Page

729 / 739

Location

England

Related Subject Headings

  • Treatment Outcome
  • Singapore
  • Self-Management
  • Reward
  • Quality-Adjusted Life Years
  • Mobile Applications
  • Middle Aged
  • Male
  • Humans
  • Health Behavior